Prostamax Side Effects

Reported Prostamax side effects

Side Effects and Safety Prostamax short-term safety signal from Russian literature is mild. Long-term pharmacovigilance is absent. Reported short-term adverse effects Gastrointestinal: mild nausea, dyspepsia (oral form). Self-limited. Local irritation (suppository form): mild rectal irritation, occasional minor discomfort. Headache: occasional mild headache. Rare allergic reactions: occasional mild rash. No serious adverse urological events attributable to Prostamax in published literature at convention dosing. Theoretical concerns Prostate cancer risk. BPH and prostate cancer are distinct diseases but occur in the same population. Chromatin-modulating peptides theoretically could affect cancer pathways if malignant cells are present. Active prostate cancer or elevated PSA under investigation is a contraindication. Drug interactions. No formal studies. Theoretical interactions with alpha-blockers, 5-alpha reductase inhibitors, PDE5 inhibitors, or other BPH/prostatitis medications have not been characterised. Hormonal interactions. Theoretical effects on androgen signalling. No empirical testing. Pregnancy and breastfeeding Not relevant — Prostamax is used in males. However, handling by pregnant partners (e.g., during pill preparation or suppository administration) should follow standard peptide precautions; finasteride has pregnancy category X contraindication for touch-handling by pregnant women, but Prostamax has no specific data on this. Paediatric use Not indicated. No paediatric safety data. Active prostate cancer Do not use Prostamax in active prostate cancer or recent history. Theoretical chromatin-modulating mechanism is not safe in proliferative disease of target organ. Elevated PSA under investigation If PSA is elevated and being worked up (new elevation, rising trend, abnormal DRE), complete the workup before considering Prostamax. Do not use to "treat" elevated PSA without diagnosis. Active urinary tract infection or bacterial prostatitis Appropriate antibiotic therapy is required. Prostamax is not a substitute. Acute urinary retention Medical emergency — catheterise and evaluate. Do not attempt to treat with bioregulators. Severe BPH with complications Patients with recurrent UTI, bladder stones, hydronephrosis, renal insufficiency from obstruction, or acute-on-chronic urinary retention require urological management, not bioregulator self-treatment. Post-prostatectomy Do not use Prostamax in the immediate post-prostatectomy period without urological approval. Wound healing and PSA surveillance dominate the recovery context. Supply quality Require third-party HPLC confirmation. For suppository form, confirm sterility and pharmaceutical-grade manufacturing. Overall assessment Short-term signal mild. Long-term absent. Particularly concerning in prostate cancer context and with elevated PSA workup. Treat as experimental with specific contraindications strictly enforced.

When to continue, reduce, or stop Prostamax

Prostamax contraindications

Contraindications Absolute contraindications Active prostate cancer or recent history Elevated PSA under investigation — complete workup first Unexplained haematuria — evaluate before use Acute urinary retention — medical emergency Active bacterial prostatitis or UTI — antibiotic therapy required Paediatric and adolescent use — not applicable Known hypersensitivity to Prostamax or any Khavinson bioregulator For extract/suppository form: bovine/porcine protein allergy Relative contraindications (supervised use only) Severe BPH with complications (recurrent UTI, bladder stones, hydronephrosis) Recent prostate surgery (within 6 weeks) Post-prostatectomy with PSA surveillance — coordinate with urology Rectal/anal disease — for suppository form Severe renal or hepatic impairment Active radiation therapy to prostate Use with caution Multiple BPH medications — alpha-blocker + 5-ARI + anticholinergic polypharmacy TRT with ongoing PSA monitoring — maintain PSA surveillance Age 80+ with polypharmacy Coagulopathy — for suppository form (rectal bleeding risk) Quality-of-supply contraindication Require third-party HPLC testing. For suppository form, pharmaceutical-grade manufacturing required. Symptoms requiring evaluation, not bioregulators Blood in urine, dysuria with fever, acute urinary retention, rising PSA, new haematospermia, weight loss with urinary symptoms, bone pain — urological evaluation required, not Prostamax self-treatment.

Why vendor quality drives Prostamax side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Prostamax side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .